tbuckley/cabot-search huggingface dataset:
2018年英国皮肤科医师协会硬化性苔癣治疗指南
Authors: F.M. Lewis, F.M. Tatnall, S.S. Velangi, C.B. Bunker, A. Kumar, F. Brackenbury, M.F. Mohd Mustapa, L.S. Exton
Journal: British Journal of Dermatology (2018)

Summary 硬化性苔癣(LS)是一种慢性皮肤病,多发于肛门和生殖器区域。本文章是一则指南,意思是,作者在科技期刊中查找了所有与LS有关的可用证据,并由此结合成针对成人(18岁以上)、儿童(0~12岁)和青少年(13~17岁)的疾病治疗的以证据为基础的最新建议。本指南由英国皮肤科医师协会的委员会撰写,遵循了评估关于本主题的所有不同研究所使用的严格标准。本指南有助于指导从事初级护理(意思是,患者出现健康问题的第一站,例如GP诊所、社区紧急处理中心)和二级护理(意思是,GP将患者送去以接受更专业护理的地方,例如医院)的医生和护士。本指南涵盖一系列问题,从治疗方案到需要解决的研究缺口。通过该指南,英国皮肤科医师协会网站(www.bad.org.uk)上创建并提供了更新的患者使用说明书。基于上述研究和专家共识,指南针对全科医师和二级护理专家提供了31条诊断和治疗LS的建议。此外,还以流程图的方式提供了适用于男性和女性的建议患者治疗方法。所有的证据都表明,有效的局部类固醇药膏是治疗此症状的最有效疗法。最初应涂抹药膏3个月,然后应根据各个患者的情况制定治疗应用的频率,以较好地控制症状和体征。指南还针对未来的研究提供了九条提议,以回答一些未解决问题,并填补了当前知识的空缺。
Author Omitted.
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction to: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients …
Journal: Circulation (2016)
Fatalities in the war in Croatia, 1991 and 1992. Underlying and external causes of death
Authors: M. Kuzman
Journal: JAMA (1993)

<h3>Objective.</h3> —To show the underlying and external causes of death and selected characteristics of those killed in the war in Croatia between March 1991 and December 1992. <h3>Design.</h3> —Analysis of 4339 fatalities recorded on two national mortality statistics documents that specified war operations as the cause of death: a demography mortality statistical form and a death certificate. <h3>Main Outcome Measures.</h3> —The frequency of clinical causes of death and their association with methods of wounding, length of survival, and attendant diagnoses. <h3>Results.</h3> —Half of those killed were men aged 21 to 35 years. Among women killed, the majority were aged 61 to 75 years. Skull fracture with intracranial injuries was the leading cause of death (28.9%), followed by multiple traumas and injuries of unspecified site (17.9%), and thoracic wounds with lung and heart injuries (17.6%). The most common methods of wounding were bombs and fragments of other explosive devices involving 1907 persons (43.9%), followed by deaths from bullet wounds (33.0%). More than 50% of those killed had sustained multiple injuries. In 78.6% of the cases, death immediately followed the wounding. (<i>JAMA</i>. 1993;270:626-628)
"The Historical Aspects of Quackery"
Authors: A. J. Clark
Journal: BMJ (1927)

<h3>Abstract</h3> Two molecular phenotypes of the acute respiratory distress syndrome (ARDS) with substantially different clinical trajectories have been identified. Classification as “hyperinflammatory” or “hypoinflammatory” depends on plasma biomarker profiling. Differences in the biology underlying these phenotypes at the site of injury, the lung, are unknown. We analyze tracheal aspirate (TA) transcriptomes from 46 mechanically ventilated subjects to assess differences in lung inflammation and repair between ARDS phenotypes. We then integrate these results with metatranscriptomic sequencing, single-cell RNA sequencing, and plasma proteomics to identify distinct features of each ARDS phenotype. We also compare phenotype-specific differences in gene expression to experimental models of acute lung injury and use an <i>in silico</i> analysis to identify candidate treatments for each phenotype. We find that hyperinflammatory ARDS is associated with increased integrated stress response and interferon gamma signaling, distinct immune cell polarization, and differences in microbial community composition in TA. These findings demonstrate that each phenotype has distinct respiratory tract biology that may be relevant to developing effective therapies for ARDS.
&lt;TITLE&gt;Children and burn injuries&lt;/TITLE&gt;
Journal: JAMA (2000)

and the AMA.The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis.For specific information concerning your personal medical condition, JAMA and the AMA suggest that you consult your physician.This page may be reproduced noncommercially by physicians and other health care professionals to share with patients.Any other reproduction is subject to AMA approval.
An American Text-book of the Diseases of Children; Including Special Chapters on Essentially Surgical Subjects—Orthopedics; Diseases of the Eye, Ear, Nose and Throat; Diseases of the Skin; and on the Diet, Hygiene and General Management of Children, by American Teachers.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Generation of Human Induced Pluripotent Stem Cells from Liver Progenitor Cells by Only Small Molecules†
Authors: Hua Liu, Yonghak Kim, Saul Sharkis, Zhaohui Ye, Yoon-Young Jang
Journal: Hepatology (2010)

We thank Moriguchi et al. for their interest in our study1 recently published in Hepatology. We share the view that tumor risk evaluation for induced pluripotent stem (iPS) cells is important and that clinical applications of human iPS cells require safe iPS generation. Our article is the first to focus on the feasibility of deriving human iPS cells from cells of human endoderm origin (i.e., human primary hepatocytes that are very short lived in vitro and thus are considered to be hard to reprogram into iPS cells) and redirecting these endoderm-derived iPS cells into multistage hepatic cells. Because we are fully aware of the importance of tumor risk evaluation for iPS cells and their derivatives, in vivo transplantation studies with our human endoderm iPS cells have been performed. So far, we have not detected any malignant transformation with hepatic cells differentiated from iPS cells when they have been transplanted into immunodeficient mouse models of chronic liver diseases. More importantly, we have also derived virus-free and integration-free human iPS cells (Fig. 1A) with an established nonviral approach,2 and we have been able to differentiate these virus-free iPS cells into hepatic endoderm cells (Fig. 1B). Therefore, we have demonstrated that the hepatic differentiation protocol that we used in our previous study1 is also applicable to the hepatic differentiation of virus-free and integration-free human iPS cells (Fig. 1). (A) Representative immunofluorescence analysis of one of the integration-free human iPS cell lines (iNF5) growing on Matrigel. The clear expression of embryonic stem cell surface antigens SSEA4 and TRA-1-60 and nuclear transcription factors OCT4 and NANOG can be observed. (B) Differentiation of iNF5 cells into hepatic cells: efficient endoderm induction of integration-free human iPS cells. Fluorescence-activated cell sorting analysis showed that approximately 80% of the induced cells expressed the definitive endoderm marker CXCR4 on day 4 after activin A treatment. Abbreviations: CXCR4, chemokine (C-X-C motif) receptor 4; DAPI, 4′,6-diamidino-2-phenylindole; OCT4, octamer 4; SSEA, stage-specific embryonic antigen. Although we have observed reliable iPS generation with the nonviral method (Fig. 1), it is less efficient than the viral protocol; the reprogramming process has been significantly longer with the nonviral method (17-35 days for the detection of iPS colonies) versus the viral method that we reported (6-14 days for the detection of iPS colonies).1 Therefore, novel reprogramming technologies that can efficiently generate safe iPS cells from mature cell types will be highly beneficial to the field. Hua Liu*, Yonghak Kim*, Saul Sharkis*, Zhaohui Ye*, Yoon-Young Jang*, * Johns Hopkins University School of Medicine, Baltimore, MD.
Transactions of the Southern Surgical and Gynecological Association.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4366: Characterization of diacetylspermine as a metabolic urinary biomarker in breast cancer using patient-derived xenografts
Authors: Thomas J. Velenosi, Kristopher W. Krausz, Frank J. Gonzalez
Journal: Cancer Research (2019)

Abstract Breast cancer is a heterogeneous disease and is currently diagnosed using clinical biomarkers to classify tumors and guide therapy. However, drug resistance is a major cause of treatment failure and current methods can only detect resistance after several months following drug therapy. Thus, there is a need for novel biomarkers to track breast cancer prognosis, diagnosis, and to monitor therapeutic efficacy. Polyamines are polycations that support the production of nucleic acids and are necessary for transcription, DNA replication and cell cycle progression. The rate-liming step in polyamine catabolism is the acetylation of spermine and spermidine by spermine/spermidine acetyl-transferase (SAT1). Indeed, diacetylspermine has been identified as a clinical urinary biomarker of early and late stage breast cancer. Despite multiple clinical studies citing the potential for diacetylspermine as a cancer biomarker, the oncogenic events contributing to increased diacetylspermine production are largely unknown. To identify metabolic biomarkers of breast cancer progression and therapeutic efficacy, an untargeted metabolomics study was performed using urine samples from mice implanted with breast cancer patient derived xenografts (PDXs). NSG mice were engrafted with a doxorubicin sensitive (Dox-Sens) or a doxorubicin resistant (Dox-Res) PDX. When tumors reached 100-200 mm3, mice were administered intravenous doxorubicin (2 mg/kg) or vehicle control once weekly for three weeks. Mice were placed in metabolic cages for 24 hours after each treatment to collect urine. At 28 days, a final 24-hour urine collection was performed in the absence of drug treatment followed by euthanization (n = 9). Untargeted metabolomics revealed diacetylspermine as the most significantly altered metabolite in urine samples by two-way repeated measures ANOVA (p = 1.26x10-11, q = 4.82 x 10-8). Urinary diacetylspermine was correlated with growth of the Dox-Sens tumors and undetectable in urine from mice with Dox-Res tumors. Remarkably, when Dox-Sens mice were treated with doxorubicin, there was a further increase in diacetylspermine despite the decrease in tumor size. These results demonstrate the potential utility of urinary diacetylspermine as a biomarker for monitoring tumor growth and doxorubicin treatment efficacy. Furthermore, these breast cancer PDX models have provided an opportunity to characterize the mechanism of oncogenic diacetylspermine production and response to drug treatment. Citation Format: Thomas J. Velenosi, Kristopher W. Krausz, Frank J. Gonzalez. Characterization of diacetylspermine as a metabolic urinary biomarker in breast cancer using patient-derived xenografts [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4366.
HYSTERICAL LOCKJAW.
Authors: GEORGE J. PRESTON
Journal: JAMA (1894)

It is always interesting to observe the manifestations of hysteria in limited and definite areas, because if ever anything like a distinct pathologic lesion is discovered it will be in such cases. Conditions causing widespread hysteria with multiform symptoms; are, like widespread lesions in the brain, too complex for purposes of minute investigation or exact localization. It is to the limited lesions that we must look for a starting point, lesions occupying areas sufficiently circumscribed to permit of thorough examination and careful comparison with corresponding normal regions. Such conditions for example as contracture of a single limb, or a single group of muscles, monoplegia, blephorospasm and the like. These minor symptoms of hysteria do not attract the same attention as the more marked and extensive manifestations of the disease, and are perhaps often overlooked by the general practitioner or at least disregarded. For the reason given above, however, it is
Revision of the Case Definition of Acquired Immunodeficiency Syndrome for National Reporting—United States
Journal: Annals of Internal Medicine (1985)

The Conference of State and Territorial Epidemiologists (CSTE) approved the following definitions regarding the case definition of acquired immunodeficiency syndrome (AIDS) at its annual meeting in June 1985. 1st, the case definition of AIDS used for national reporting will continue to include only the more severe manifestations of human T-lymphotropic virus type III (HTLV-III) infection. 2nd, Centers for Disease Control (CDC) will develop more inclusive definitions and classifications of HTLV-III infection for diagnosis, treatment, and prevention, as well as for epidemiologic studies and special surveys. 3rd, a number of refinements will be adopted in the case definition of AIDS used for national reporting. In the absense of the opportunistic diseases required by the current case definition, disseminated histoplasmosis, isosporiasis, bronchial or pulmonary candidiasis, non-Hodgkin's lymphoma of high-grade pathologic type, and histologically confirmed Kaposi's sarcoma in patients 60 years or over will be considered indicative of AIDS if the patient has a positive serologic or virologic test for HTLV-III. Also, in the absence of the required opportunistic diseases, a histologically confirmed diagnosis of chronic lymphoid insterstitial pneumonitis in a child under 3 years of age will be considered indicative of AIDS unless HTLV-III antibody tests are negative. Patients who have a lymphoreticular malignancy diagnosed more than 3 months after the diagnosis of an opportunistic disease used as a marker for AIDS will no longer be excluded as AIDS cases. Finally, to increase the specificity of the case definition, patients will be excluded as AIDS cases if they have a negative result on testing for serum antibody to HTLV-III, have no other test for HTLV-III with a positive result, and do not have a low number of T-helper lymphocytes or a low T4:T8 ratio.
Osteosclerotic Myeloma
Authors: Antonio R. Rodriguez
Journal: JAMA (1976)

A 49-year-old man with an osteosclerotic lesion of a thoracic vertebra had peripheral neuropathy, lymphadenopathy, and elevated serum alkaline phosphatase and monoclonal immunoglobulin levels in the cerebrospinal fluid. These findings, not usually seen in "classical" myeloma, have been noted in different combinations in the osteosclerotic variety. (<i>JAMA</i>236:1872-1874, 1976)
THE SAN FRANCISCO SESSION
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cover Story: Sir Alfred Baring Garrod, FRS
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ITALY
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal